About nanoviricides - NNVC
NanoViricides, Inc. is a clinical stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.
NNVC At a Glance
NanoViricides, Inc.
1 Controls Drive
Shelton, Connecticut 06484
| Phone | 1-203-937-6137 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -8,294,146.00 | |
| Sector | Health Technology | Employees | 7 | |
| Fiscal Year-end | 06 / 2025 | |||
| View SEC Filings |
NNVC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.972 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.014 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
NNVC Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,184,878.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NNVC Liquidity
| Current Ratio | 3.658 |
| Quick Ratio | 3.658 |
| Cash Ratio | 3.531 |
NNVC Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -55.81 |
| Return on Equity | -63.002 |
| Return on Total Capital | -72.349 |
| Return on Invested Capital | -63.002 |
NNVC Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |